Acute Application of Pegvisomant and Octreotide in Acromegaly

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ludwig-Maximilians - University of Munich
• Treatments: Cabergoline; Dopamine; Dopamine Agonists; Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• patients with acromegaly currently on stable pegvisomant therapy

• patients with diabetes mellitus may be included. Glucose levels must be controlled regularly throughout the study

• patients must not be co-treated with any other medication for acromegaly

Exclusion Criteria:

• radiotherapy within the last 2 years

• any relevant acute disease

• history of hypersensitivity against any of the used drugs

• pregnancy or lactation

• abnormal baseline findings